Q2 EPS Estimates for Oruka Therapeutics Lowered by Wedbush

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities researchers at Wedbush lowered their Q2 2025 earnings estimates for shares of Oruka Therapeutics in a report issued on Wednesday, May 14th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.46) per share for the quarter, down from their previous forecast of ($0.43). Wedbush has a “Outperform” rating and a $40.00 price objective on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share. Wedbush also issued estimates for Oruka Therapeutics’ Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.82) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.05) EPS, FY2027 earnings at ($2.52) EPS and FY2028 earnings at ($3.34) EPS.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.17.

Several other analysts have also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, February 7th. Wolfe Research began coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 price target on the stock. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $39.86.

Oruka Therapeutics Trading Up 3.0%

Shares of Oruka Therapeutics stock opened at $10.62 on Monday. The firm has a market cap of $397.62 million, a PE ratio of -1.70 and a beta of 0.25. The stock has a 50 day moving average of $9.83 and a 200 day moving average of $14.54. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $31.13.

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. purchased a new stake in shares of Oruka Therapeutics in the fourth quarter valued at $54,000. AlphaCentric Advisors LLC bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $119,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Oruka Therapeutics in the 4th quarter worth $144,000. AlphaQuest LLC purchased a new stake in Oruka Therapeutics in the first quarter worth about $168,000. Finally, Cannon Global Investment Management LLC bought a new position in Oruka Therapeutics during the 1st quarter worth about $195,000. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.